BeiGene, Ltd. - American Depositary Shares (NQ:BGNE)

184.71 UNCHANGED

Last Price Updated: 4:00 PM EST, Dec 31, 2024 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about BeiGene, Ltd. - American Depositary Shares

< Previous 1 2

...

10 11 12 13 14 15 16 17 Next >

BeiGene to Demonstrate Strength of Hematology Portfolio and Pipeline at European Hematology Association 2022 Congress

May 12, 2022

From BeiGene

Via Business Wire

52 Stocks Moving In Wednesday's Mid-Day Session ↗

May 11, 2022

Gainers Trecora Resources (NYSE: TREC) shares jumped 26.6% to $9.56 as the company agreed to be acquired by an affiliate of Balmoral Funds at $9.81 per share in cash or an enterprise value of $247...

Via Benzinga

Where BeiGene Stands With Analysts ↗

May 09, 2022

Within the last quarter, BeiGene (NASDAQ:BGNE) has observed the following analyst ratings:

Via Benzinga

Novartis - BeiGene's Tislelizumab Aces Late-Stage Esophageal Cancer Trial ↗

April 27, 2022

Via Benzinga

BeiGene Shares Updated Data From Tislelizumab Combo Trial In Head & Neck Cancer ↗

April 19, 2022

Via Benzinga

99 Biggest Movers From Yesterday ↗

May 12, 2022

Gainers Armstrong Flooring, Inc. (NYSE: AFI) shares jumped 237% to settle at $0.49 on Wednesday after a 13D filing showed Esopus Creek Advisors LLC disclosed a 5.1% active stake in the company.

Via Benzinga

Week in Review: VectorBuilder Plans $500 Million Gene Therapy Delivery CDMO in Guangzhou ↗

April 16, 2022

Deals, financings, trials and approvals in biotech in China this week.

Via Talk Markets

Why Roche's Flop In Lung Cancer Hammered Arcus, Iteos And Others ↗

May 11, 2022

Roche isn't the only company working on an anti-TIGIT molecule.

Via Investor's Business Daily

34 Stocks Moving in Wednesday's Pre-Market Session ↗

May 11, 2022

Gainers Embark Technology, Inc. (NASDAQ: EMBK) rose 36.4% to $1.95 in pre-market trading. Embark Technology posted a Q1 loss of $0.04 per share.

Via Benzinga

Week In Review: OrbiMed Plans To Raise $1.1 Billion For Fifth Asia Fund ↗

May 07, 2022

One year after raising $3.5 billion for three funds in 2021, OrbiMed, the world’s largest healthcare-dedicated investor, is back with plans for $4.75 billion in new funds despite the slowdown in...

Via Talk Markets

Recap: BeiGene Q1 Earnings ↗

May 05, 2022

BeiGene (NASDAQ:BGNE) reported its Q1 earnings results on Thursday, May 5, 2022. Here's what investors need to know about the announcement. Earnings BeiGene beat estimated earnings by 10.36%, reporting...

Via Benzinga

HFCAA News: 128 Chinese Stocks the SEC Could Delist ↗

May 05, 2022

The SEC has released a massive list of Chinese stocks that could face delisting on Holding Foreign Companies Accountable Act news.

Via InvestorPlace

BeiGene Reports First Quarter 2022 Financial Results

May 05, 2022

From BeiGene, Ltd.

Via Business Wire

BeiGene Announces the Approval in China of BLINCYTO® (Blinatumomab) for Injection for Pediatric Patients with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (ALL)

May 04, 2022

From BeiGene

Via Business Wire

BeiGene Breaks Ground on New Manufacturing and Clinical R&D Center at the Princeton West Innovation Campus in New Jersey

April 29, 2022

From BeiGene

Via Business Wire

BeiGene Announces BRUKINSA (zanubrutinib) Approval in Uruguay in Mantle Cell Lymphoma, Marginal Zone Lymphoma, and Waldenström’s Macroglobulinemia

April 28, 2022

From BeiGene

Via Business Wire

BeiGene to Present Clinical Data from Innovative Oncology Portfolio at 2022 ASCO Annual Meeting

April 27, 2022

From BeiGene

Via Business Wire

The Daily Biotech Pulse: Molecular Partners Plunges On Double Bad News, Pfizer/BioNTech Seek Nod For COVID-19 Shot In Kids, Pfizer Invests In Zentalis ↗

April 27, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours.

Via Benzinga

Global Phase 3 Trial of BeiGene’s PD-1 Inhibitor, Tislelizumab, in Combination with Chemotherapy Meets Primary Endpoint in First-Line Advanced Esophageal Squamous Cell Carcinoma

April 27, 2022

From BeiGene

Via Business Wire

The Daily Biotech Pulse: Protagonist's Ulcerative Colitis Study Disappoints, Gilead's Remdesivir Approved For Pediatric COVID-19 Patients, FDA Gives Nod To Gamida's Cell Therapy Trial, Fast Track Tag For Vascular Biogenics Ovarian Cancer Gene Therapy ↗

April 26, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

BeiGene Introduces Global Environmental, Social, and Governance Strategy

April 26, 2022

From BeiGene, Ltd.

Via Business Wire

BeiGene Provides Grant to Crossroads4Hope to Fund Psychosocial Support Programs for Cancer Patients and Communities in New Jersey

April 21, 2022

From BeiGene

Via Business Wire

InnoCare Pharma Goes Back to Funding Trough With STAR Market Listing ↗

April 19, 2022

Key Takeaways: InnoCare Pharma’s A-share IPO will make it the fourth innovative pharma company with shares traded in Hong Kong and on the mainland’s STAR Market...

Via Benzinga

BeiGene Presents Updated Results from Phase 3 RATIONALE-309 Trial of PD-1 Inhibitor Tislelizumab in First-Line RM-NPC in Virtual ASCO Plenary Series

April 19, 2022

From BeiGene

Via Business Wire

China NMPA Approves Tislelizumab for Patients with Second-Line Esophageal Squamous Cell Carcinoma

April 15, 2022

From BeiGene

Via Business Wire

BeiGene's Brukinsa Tops JNJ's Imbruvica In Overall Response Rate In Leukemia Study ↗

April 11, 2022

BeiGene Ltd (NASDAQ: BGNE) has announced results from the Phase 3 ALPINE trial of Brukinsa (zanubrutinib) in relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic...

Via Benzinga

Cancer Drug Maker BeiGene Takes Action to Mitigate Delisting Risk ↗

April 11, 2022

Key Takeaways: BeiGene has switched auditors for its New York listing to a U.S. company from a Chinese one in a move to comply with U.S. law The change could reduce the company...

Via Benzinga

IRC Determines BRUKINSA® (Zanubrutinib) Demonstrates Superior Overall Response Rate Versus Ibrutinib in Final Response Analysis of ALPINE Trial in Chronic Lymphocytic Leukemia

April 11, 2022

From BeiGene, Ltd.

Via Business Wire

BeiGene to Present Clinical Results and Biomarker Data on Tislelizumab in Solid Tumors at the AACR Annual Meeting 2022

April 08, 2022

From BeiGene

Via Business Wire

The Daily Biotech Pulse: BioXcel's Igalmi Gets FDA Nod, Citius Spikes On Positive Phase 3 Data, Iovance Receives Positive Regulatory Feedback For Skin Cancer Therapy ↗

April 06, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours.

Via Benzinga

< Previous 1 2

...

10 11 12 13 14 15 16 17 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.